Screener
Insulet PODD U.S. — Total Revenue
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Insulet in its filing.
Tagged under the XBRL concept us-gaap:Revenues.
The source filing: Insulet’s 10-Q, filed August 5, 2026.
- Filed
- Aug 5, 2026, 4:06 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001145197-26-000169
| (in millions) | Three Months Ended June 30, 2026 | Three Months Ended June 30, 2025 | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|---|---|
| U.S. | $549.9 | $463.3 | $1,068.8 | $879.9 |
| International | 251.8 | 185.8 | 494.6 | 338.1 |
| Total revenue | $801.7 | $649.1 | $1,563.4 | $1,218.1 |
Item 1. Condensed Consolidated Financial Statements (Unaudited)
FAQ
- What is Insulet's U.S. — total revenue?
- Insulet (PODD) reported U.S. — total revenue of $549.9M in Q2 2026.
- How has Insulet's U.S. — total revenue changed year-over-year?
- Insulet's U.S. — total revenue increased by 18.7% year-over-year, from $463.3M to $549.9M.
- What is the long-term trend for Insulet's U.S. — total revenue?
- Over 4 years (2021 to 2025), Insulet's U.S. — total revenue has grown at a 27.5% compound annual growth rate (CAGR), from $738.9M to $1.95B.
- What does U.S. — total revenue mean?
- This metric represents the total gross sales generated from the sale of medical devices and associated supplies within the United States market. It reflects the company's ability to capture market share, drive adoption of insulin management systems, and execute commercial strategies in its primary domestic region.
Ask your AI about Insulet's u.s. — total revenue.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude